Trial Profile
A Randomized, Open-Label, Phase 2 Trial of CMB305 (Sequentially Administered LV305 and G305) and Atezolizumab in Patients With Locally Advanced, Relapsed, or Metastatic Sarcoma Expressing NY-ESO-1
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 13 Dec 2023
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; CMB 305 (Primary) ; G 305 (Primary) ; LV 305 (Primary)
- Indications Liposarcoma; Myxoid liposarcoma; Soft tissue sarcoma; Synovial sarcoma
- Focus Therapeutic Use
- Sponsors Immune Design
- 14 Jul 2021 Results published in the Journal of Clinical Oncology
- 26 Jun 2020 Status changed from completed to discontinued.
- 16 May 2019 Status changed from active, no longer recruiting to completed.